Form 4: Greenwich LifeSciences VP Acquires 1,000 Shares

Jaye Thompson, VP of Clinical Regulatory Affairs at Greenwich LifeSciences, acquired 1,000 shares of common stock at $12.91 per share on November 21, 2024.

Summary

• Jaye Thompson, the VP of Clinical Regulatory Affairs at Greenwich LifeSciences, purchased 1,000 shares of the company's common stock.
• The transaction occurred on November 21, 2024.
• The purchase price was $12.91 per share.
• Following the transaction, Thompson directly owns 264,148 shares of Greenwich LifeSciences stock.

Sentiment

Score: 6

Explanation: The document is a neutral disclosure of a stock purchase by a company officer. It is neither particularly positive nor negative, but the purchase could be interpreted as a sign of confidence.

Positives

• The purchase of shares by a company officer can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the trading activities of company officers.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for all publicly listed companies, including those in the biotechnology sector like Greenwich LifeSciences.
• Similar filings are made by officers and directors of companies such as Amgen, Regeneron, and Gilead Sciences when they trade their company's stock.
• The volume of shares purchased is relatively small compared to the overall market capitalization of the company, which is typical for individual officer transactions.

Stakeholder Impact

• The purchase of shares by a company officer may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Greenwich LifeSciences, GLSI, insider trading, stock purchase, Jaye Thompson, common stock, SEC Form 4